title: The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).
authors.affiliation: Department of Haematology, Hospital La Fe, Valencia, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Montesinos
authors.affiliation: Department of Haematology, Hospital Clínico, Salamanca, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Cabrero
authors.affiliation: Department of Haematology, Hospital Vall d'Hebron, Barcelona, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Valcárcel
authors.affiliation: Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.affiliation: Department of Haematology, Hospital Puerta de Hierro, Majadahonda, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: García-Marco
authors.affiliation: Department of Haematology, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Loscertales
authors.affiliation: Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Moreno
authors.affiliation: Department of Haematology, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Duarte
authors.affiliation: Department of Haematology, Hospital Clínic, Valencia, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Terol
authors.affiliation: Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Villamor
authors.affiliation: Department of Haematology, Hospital Vall d'Hebron, Barcelona, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Abrisqueta
authors.affiliation: Department of Haematology, Hospital Clínico, Salamanca, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Caballero
authors.affiliation: Department of Haematology, Hospital La Fe, Valencia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Sanz
authors.affiliation: Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Delgado
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000032:analysis; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012008:Recurrence; D012307:Risk Factors; D055502:Secondary Prevention; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods* / Q000401:mortality; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; C527517:ofatumumab